Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
144.4 USD | +0.26% | +11.48% | +22.19% |
Apr. 26 | CR Double-Crane Pharmaceutical's Profit Rises 11% in Q1 as Revenue Grows 2% | MT |
Apr. 26 | CR Double-Crane Pharmaceutical's Unit Gets Nod to Trial New Pain Medication | MT |
Financials (USD)
Sales 2024 * | 2.3B | Sales 2025 * | 2.44B | Capitalization | 8.24B |
---|---|---|---|---|---|
Net income 2024 * | 282M | Net income 2025 * | 327M | EV / Sales 2024 * | 3.56 x |
Net cash position 2024 * | 37.28M | Net cash position 2025 * | 370M | EV / Sales 2025 * | 3.22 x |
P/E ratio 2024 * |
29.5
x | P/E ratio 2025 * |
25.3
x | Employees | 7,000 |
Yield 2024 * |
0.56% | Yield 2025 * |
0.63% | Free-Float | 85.41% |
Latest transcript on Crane Company
1 day | +0.26% | ||
1 week | +11.48% | ||
Current month | +6.82% | ||
1 month | +7.01% | ||
3 months | +27.74% | ||
6 months | +58.21% | ||
Current year | +22.19% |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.05% | 773 M€ | -.--% | - | |
0.04% | 20 M€ | -.--% | - | |
0.00% | 34 M€ | +2.14% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 144.4 | +0.26% | 276,356 |
24-04-25 | 144 | +1.30% | 400,766 |
24-04-24 | 142.1 | +2.91% | 496,653 |
24-04-23 | 138.1 | +5.65% | 424,342 |
24-04-22 | 130.7 | +0.97% | 265,223 |
Delayed Quote Nyse, April 26, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.19% | 8.24B | |
+11.20% | 15.36B | |
-3.28% | 6.73B | |
+35.50% | 1.97B | |
+0.49% | 1.51B | |
+26.34% | 975M | |
+0.92% | 845M | |
+9.29% | 751M | |
-5.19% | 675M | |
-20.92% | 402M |
- Stock Market
- Equities
- CR Stock